|
|
Volumn 46, Issue 3, 2010, Pages 195-230
|
|
Marching against blood diseases: A report from the 51st Annual Meeting of the American Society of Hematology (December 5-8, 2009 - New Orleans, Lousiana, USA)
a
a
I3 Research
(Spain)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
ACETYLSALICYLIC ACID;
ALEMTUZUMAB;
ALPHA INTERFERON;
ARSENIC TRIOXIDE;
ASPARAGINASE;
ASPARAGINASE MACROGOL;
AZACITIDINE;
BUSULFAN;
CLOFARABINE;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DAUNORUBICIN;
DEXAMETHASONE;
DOXORUBICIN;
ENOXAPARIN;
FLUDARABINE;
FONDAPARINUX;
IMATINIB;
MELPHALAN;
MERCAPTOPURINE;
METHOTREXATE;
PREDNISOLONE;
PREDNISONE;
RITUXIMAB;
RIVAROXABAN;
THALIDOMIDE;
THYMOCYTE ANTIBODY;
UNINDEXED DRUG;
VINCRISTINE;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ACUTE LYMPHOCYTIC LEUKEMIA;
ANEMIA;
ANTICOAGULATION;
BLEEDING;
BLOOD CLOTTING DISORDER;
CLINICAL RESEARCH;
CONFERENCE PAPER;
DRUG COST;
DRUG RESEARCH;
HEMATOLOGIC MALIGNANCY;
HODGKIN DISEASE;
HUMAN;
MEDICAL SOCIETY;
MYELOFIBROSIS;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PROGRESSION FREE SURVIVAL;
THROMBOEMBOLISM;
THROMBOSIS;
THROMBOSIS PREVENTION;
UNITED STATES;
ANIMALS;
ANTINEOPLASTIC AGENTS;
BLOOD CELLS;
DRUG DELIVERY SYSTEMS;
HEMATOLOGIC DISEASES;
HEMATOLOGIC NEOPLASMS;
HUMANS;
|
|
EID: 77954115442
PISSN: 16993993
EISSN: 16994019
Source Type: Journal
DOI: 10.1358/dot.2010.46.3.1490753 Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
